Skin rash as useful marker of erlotinib efficacy in NSCLC and its impact on clinical practice.
The result's identifiers
Result code in IS VaVaI
<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F26475821%3A_____%2F12%3A%230000137" target="_blank" >RIV/26475821:_____/12:#0000137 - isvavai.cz</a>
Result on the web
—
DOI - Digital Object Identifier
—
Alternative languages
Result language
angličtina
Original language name
Skin rash as useful marker of erlotinib efficacy in NSCLC and its impact on clinical practice.
Original language description
Erlotinib is a low molecular weight inhibitor of tyrosine kinase receptor for epidermal growth factor. In clinical practice it is used for the treatment of advanced stages of NSCLC. Papulopustular rash (rash) is the most common manifestation of erlotinibskin toxicity. Poster presenting the data from analysis represents the occurrence of rash as a predictor of treatment effect of erlotinib in patients carrying the wild-type EGFR and KRAS wild-type genes and assessment of its possible use in clinical practice.
Czech name
—
Czech description
—
Classification
Type
O - Miscellaneous
CEP classification
FD - Oncology and haematology
OECD FORD branch
—
Result continuities
Project
<a href="/en/project/NS9718" target="_blank" >NS9718: New possibilities for application of molecular-diagnostic methods for early detection and proper therapy selection of progressing Non-Small Cell Lung Cancer based on detection and monitoring of hypermethylation of specific genes</a><br>
Continuities
P - Projekt vyzkumu a vyvoje financovany z verejnych zdroju (s odkazem do CEP)
Others
Publication year
2012
Confidentiality
S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů